Allscripts vs adyn
Side-by-side comparison of AI visibility scores, market position, and capabilities
Rebranded to Veradigm Jan 2023; $620-635M revenue expected 2024; 180K+ physician users; 3.6% ambulatory EHR market share; sold hospital business to Harris Computer $700M 2022; Nasdaq suspended Feb 2024
About
Allscripts is a healthcare IT company founded in 1986 in Chicago, historically one of the largest providers of electronic health record and practice management software for physician practices and hospitals in the United States. The company rebranded to Veradigm in January 2023, signaling a strategic pivot from legacy EHR software toward data analytics, life sciences research enablement, and healthcare network intelligence — areas where its 180,000+ physician user base and de-identified patient data assets create differentiated value for pharmaceutical and payer customers.\n\nThe Veradigm platform combines its ambulatory EHR and practice management software with a data and analytics layer that aggregates real-world clinical data for life sciences research, post-market drug surveillance, and population health analytics. Its network of physician practices represents one of the largest ambulatory data footprints in the US, making Veradigm a valuable partner for pharmaceutical companies seeking real-world evidence and patient registries. The company maintains a 3.6% share of the ambulatory EHR market while building out higher-margin analytics and data licensing revenue streams.\n\nVeradigm (formerly Allscripts) targets $620–635M in revenue for 2024, serving 180,000+ physician users across its installed EHR base. The rebrand to Veradigm reflects management's intent to migrate the business model from competitive, commoditizing EHR software toward network and data platform economics. As life sciences companies increase investment in real-world evidence and physicians demand more integrated practice intelligence tools, Veradigm's combination of clinical workflow reach and data network assets gives it a credible platform for this strategic repositioning.
Precision birth control test using hormone and genetic data to personalize contraceptive selection; $2.65M from Lux Capital and M13 addressing trial-and-error that leaves millions on wrong contraceptives.
About
adyn is a precision medicine company developing personalized birth control solutions through at-home testing kits that analyze hormone levels and genetic risk factors — enabling individuals to choose hormonal contraceptives based on their own biology rather than trial-and-error, addressing a gap where most people cycle through multiple birth control options over years to find what works without causing intolerable side effects. Founded in 2019 and a Y Combinator graduate, adyn raised $2.65 million in seed funding co-led by Lux Capital and M13, with the Birth Control Optimization Test positioned as the first biology-based test for contraceptive personalization.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.